聚合体抑制复合体2抑制黑色素瘤细胞中对干扰素敏感的MHC-II表达,并与抗PD-1耐药性相关
Jamaal L James1, Brandie C Taylor1, Margaret L Axelrod2
1Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Journal for immunotherapy of cancer
|February 5, 2024
概括
向EZH2增强了瘤特异性的MHC-II表达,可能克服对免疫治疗的耐药性. 这项研究揭示了EZH2抑制是改善黑色素瘤抗PD-1/PD-L1治疗疗效的有希望的策略.
科学领域:
- 免疫学 免疫学 免疫学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
背景情况:
- 黑色素瘤免疫疗法耐药性机制尚未完全理解.
- 特定于瘤的MHC-II (tsMHC-II) 上调预测了对抗PD-1/PD-L1疗法的反应.
- 控制TSMHC-II表达的遗传和表观遗传途径需要进一步的表征.
研究的目的:
- 研究聚合体抑制复合体2 (PRC2) /EZH2信号在tsMHC-II抑制中的作用.
- 确定EZH2抑制是否可以增强tsMHC-II表达并改善免疫治疗反应.
- 阐明了TSMHC-II调控背后的表观遗传机制.
主要方法:
- 从接受抗PD-1治疗的患者的黑色素瘤瘤活检的RNA测序.
- 有针对性的抑制试验,以评估EZH2对MHC-II通路的影响.
- 用测序 (ATAC-seq) 检测转化酶可访问的染色质,以评估染色质的可访问性.
主要成果:
- 增加EZH2通路mRNA表达与MHC-II和T细胞基因表达相反相关.
- 在IFN-γ刺激后,EZH2抑制调节的MHC-II通路诱导性.
- 在转移性黑色素瘤患者中,较高的PRC2相关基因表达与对抗PD-1治疗的反应较差有关.
结论:
- 抑制EZH2增强MHC-II的表达,可能是通过CIITA改善的染色质可访问性.
- 向EZH2提供了一种潜在的策略,以克服tsMHC-II抑制并提高免疫治疗的疗效.
- 这些发现提供了有关黑色素瘤免疫疗法耐药性和EZH2.2治疗向性的见解.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


